New processing technology for colistmethate sodium, leading to improved and cost-effective formulations for pharmaceutical and veterinary markets

Información del proyecto

PROTOCOL

Identificador del acuerdo de subvención: 673280

DOI

10.3030/673280

Proyecto cerrado

Fecha de la firma de la CE 23 Abril 2015

Fecha de inicio 1 Mayo 2015

Fecha de finalización 31 Octubre 2015

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

CIDQO 2012 SL
Spain

Periodic Reporting for period 1 - PROTOCOL (New processing technology for colistmethate sodium, leading to improved and cost-effective formulations for pharmaceutical and veterinary markets)

Período documentado: 2015-05-01 hasta 2015-10-31

Resumen del contexto y de los objetivos generales del proyecto

The PROTOCOL project (new PROcessing Technology fOr COListmethate sodium, leading to improved and cost-effective formulations for pharmaceutical and veterinary markets) aimed through SME Instrument Phase 1 to perform a thorough feasibility study to verify the practical and economic viability in Pharmaceutical and Veterinary markets of the CMS form. The specific objectives that were defined, and have been covered in the frame of the 1st Stage of SME Instrument are:
- To develop a business and exploitation plan.
- To undertake a commercial feasibility assessment.
- To widely disseminate project outcomes.
- To define the best practices for IPR management.
- To analyze in detail the regulatory standards to be met.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

The general goal of the current project is to fulfill the need of decreasing the current CMS market price and to undertake an innovation project to solve this limitation, through a new process to obtain CMS. In this sense, CIDQO has concluded that carrying the innovation project and launching CMS on the company’s specifications can be a successful business.

This period of time has been useful for specifying relevant elements of the business model and the tasks regarding to develop the exploitation model, undertaking the commercial feasibility assessment comprising logistics and marketing plan, disseminating the project outcomes, define the best practices for IPR management and analysing in detail the regulatory standards in order to ensure the success for commercial exploitation of the PROTOCOL’s results.

Summarizing:
• Launching CIDOQ’s cost-effective CMS through the new processing technology is a project with high margin
• A full market study has been undertaken.
• An IP study has been carried out.
• The project outcomes have been widely disseminated.
• SME Instrument Phases II and III will further develop the innovation.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

The expected growth of the company after the current SME Instrument Phase 1 and the subsequent Phase 2 will be very important. CIDQO should increase its net incomes and hence it foresees the creation of several new employments.

COListmethate sodium